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Background: The identification of suited early detection tests is one among the multiple requirements to reduce
cervical cancer incidence in developing countries.
Methods: We evaluated p16INK4a/Ki-67 dual-stain cytology in a screening population in Thika district, Kenya and
compared it to high-risk human papillomavirus (HR-HPV) DNA testing and visual inspection by acetic acid (VIA) and
Lugol’s iodine (VILI).
Results: Valid results for all tests could be obtained in 477 women. 20.9 % (100/477) were tested positive for HR-HPV
DNA, 3.1 % (15/477) had positive VIA/VILI and 8.2 % (39/477) positive p16INK4a/Ki-67 cytology. Of 22 women that showed
up for colposcopy and biopsy, 6 women were diagnosed with CIN3 and two with CIN2. All women with CIN2/3 were
negative in VIA/VILI screening and positive by HR-HPV DNA testing. But HPV was also positive in 91.7 % (11/12) of women
with normal histology. p16INK4a/Ki-67 cytology was positive in all 6 women with CIN3, in one of the two CIN2 and in only
8.3 % (1/12) of women with normal histology.
Conclusions: p16INK4a/Ki-67 cytology is an interesting test for further studies in developing countries, since our findings
point to a lower fraction of false positive test results using p16INK4a/Ki-67 cytology compared to HPV DNA testing in a
Kenyan screening population. VIA/VILI missed all histology-proven CIN2/3.
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Cancer of the uterine cervix is the third most common
cancer in women around the world and still the leading
cancer in women in Sub Sahara Africa [1]. Of the
450,000 new cases every year, over 80 % occur in re-
source poor countries [1]. In Kenya, the annual crude
incidence rate of cervical cancer is 16.5 per 100,000
women with a leading mortality rate of 13.5 in 100,000
women [1, 2].
Implementation of nationwide screening for cervical
cancer has been successful in reducing the incidence
and mortality rates of cervical cancer in many countries
[3]. A further reduction in disease incidence is suggested
to be reached by prophylactic HPV vaccinations, if they
are combined with continued screening [4]. However,* Correspondence: miriam.reuschenbach@med.uni-heidelberg.de
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tries is dramatically low. In Kenya, only 3.2 % of the fe-
male population aged 18–69 have been screened for
cervical cancer [2].
Cervical cancer is caused by long lasting infections of
the cervical squamous cell epithelium with human papil-
lomaviruses (HPV). The infection is usually acquired
during adolescence when women become sexually active
and infection prevalence my reach over 50 % [5]. While
the vast majority of women clear the infection, upon
persistent HPV infections premalignant alterations (cer-
vical intraepithelial neoplasia, CIN) may occur after sev-
eral years, which precede the development of cervical
cancer. Cervical cancer is largely preventable by detect-
ing premalignant alterations and treat them by ablation
or excisional means [5].
Currently the primary screening tests for cervical can-
cer in most countries with implemented screening pro-
grams is Pap cytology, where a smear is taken from theticle distributed under the terms of the Creative Commons Attribution License
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light microscope for neoplastic alterations. Pap screening
requires advanced infrastructures and experience as it is
characterized by multiple visits for diagnosis and treat-
ment, because it has a low single-test sensitivity of be-
tween 55 to 80 % [6, 7] and generates many equivocal
results which need further work-up [8]. Before women
are referred to treatment, classically by removal of the
affected tissue (conization), the test is repeated, the cer-
vix is assessed visually by colposcopy and diagnostic bi-
opsies are taken. Overall Pap cytology-based screening
has frequently proven challenging and unworkable in
low-resource settings [9].
Different programs investigate and assess alternative ap-
proaches, particularly the use of visual screening methods,
such as visual inspection with acetic acid (VIA), for pre-
cancer and cancer detection and the use of cryotherapy as
a pre-cancer treatment method. This is optimally achieved
in a single visit and can be carried out also by competent
non-physicians, including nurses and midwives. Because
the diagnostic accuracy of VIA is largely heterogeneous, in
some setting only reaching a sensitivity of ~40 % [10] and
thereby missing women with pre-cancer that would need
treatment, still alternative tests suited for rural and limited
resource conditions are currently designed and should be
scientifically evaluated.
Detecting the viral DNA is a highly sensitive test for
cervical cancer early detection, detecting more premalig-
nant alterations than Pap cytology, used in addition to
Pap cytology in certain settings and currently introduced
as an alternative for primary screening in many industri-
alized countries [11]. However, considering the high
prevalence of HPV infections, particularly in young
women, detecting HPV DNA is a poorly specific test for
real cellular alterations and therefore requires additional
triage tests for the specific identification of women need-
ing further work-up or treatment [12]. Much effort is
currently spent in evaluating the clinical performance of
new biomarkers, in order to reduce referral rates, un-
necessary treatments and finally costs. In developing
countries new biomarkers are particularly attractive as
potential point-of-care tests. They can be used to specif-
ically identify directly at one visit those women that
need treatment and may thereby reduce the lost-to-
follow-up rate [13].
There are different biomarkers that have been identified
and suggested to improve diagnosis of cervical cancer and
its precancerous lesions. One promising marker is the cyc-
lin dependent kinase inhibitor p16INK4a, which becomes
overexpressed in response to viral oncogene E7 expression
[14]. A number of studies have investigated the clinical use
of p16INK4a as a specific biomarker for cells with transform-
ing HPV infections [15]. HPV-transformed cells overex-
press p16INK4a but retain the capacity to proliferate and arethus double-positive for p16INK4a and the proliferation
marker Ki-67, while senescent cells express p16INK4a but
are Ki-67 negative [16]. An immunochemical test which in
parallel detects p16INK4a and the proliferation marker Ki-67
(p16INK4a/Ki-67 cytology, CINtec PLUS) is designed for ap-
plication on cytologic smears taken from the uterine cervix
with a brush, spread on a glass slide, stained for expression
of the two markers and assessed under a light microscope.
The test demonstrated high sensitivity comparable to HPV
DNA testing but superior specificity compared to HPV
DNA testing in a European screening population [15, 17].
The objective of the present study was to study over-
all positivity rates of p16INK4a/Ki-67 cytology in a
screening population of Kenyan women and compare
it to VIA/VILI and HPV DNA testing. Additionally the
study was designed to evaluate the diagnostic perform-
ance of the tests to detect high grade CIN.
Results
Characteristics of the study population and proportion of
positive VIA/VILI, HPV and p16INK4a/Ki-67 results
A total of 498 women met the eligibility criteria. After ex-
clusion of women with incomplete personal information
(no age documented), no VIA/VILI and/or invalid labora-
tory results in either Pap cytology (low cell number),
p16INK4a/Ki-67 cytology (low cell number) and/or HPV
DNA (no cell pellet), 477 samples remained for evaluation.
Mean age of these 477 study participants was 35.6 years,
ranging between 18 and 74 years (standard deviation
9.9 years). A detailed socio-demographic characterization of
the study population is given in reference [18].
p16INK4a/Ki-67 cytology was positive in 8.2 % (39/477)
of the women, with highest rate of positivity in women
of age 36 to 40 years (12.2 %, 10/82) and no positives in
women younger than 21 years (Fig. 1).
Of the 477 women, 20.9 % (100/477) were tested posi-
tive for HR-HPV. Highest HPV prevalence was found
with 35.7 % (5/14) among women younger than 21 years
(18–20 years) and prevalence decreased with older age
groups with the lowest prevalence (8.3 %, 1/12) in those
older than 55 years (Fig. 1).
VIA/VILI was only positive in a total of 3.1 % (15/477)
of the women with the highest prevalence in the age
group 46 to 50 years (9.8 %, 4/41) and no positives in
women younger than 21 or older than 55 years (Fig. 1).
Most women had normal cytology (89.3 %, 426/477),
2.9 % (14/477) had LSIL, 0.2 % (1/477) AGUS, 5.5 %
(26/477) ASCUS and 2.1 % (10/477) had HSIL diagnosed
in Pap cytology (Table 1).
Correlation of VIA/VILI, HPV results and p16INK4a/Ki-67
cytology
Agreements between VIA/VILI, HPV results and p16INK4a/
Ki-67 cytology are shown in Table 2. Poor agreement was
Fig. 1 Proportion of positive VIA/VILI, HR-HPV tests and positive
p16INK4a/Ki-67 dual-stain cytology in different age groups
Table 1 Proportion of positive VIA/VILI, HPV DNA and p16INK4a/Ki-67
Women with normal colposcopy that were not biopsied (n = 4) are
Total n VIA/VILI positive
Colposcopy/histology
Normal 12 0 (0.0 %)
CIN1 2 0 (0.0 %)
CIN2 2 0 (0.0 %)
CIN3 6 0 (0.0 %)
Not available 455 15
Pap cytology
Normal 426 9 (2.1 %)
LSIL 14 0 (0.0 %)
AGUS 1 0 (0.0 %)
ASCUS 26 3 (11.5 %)
HSIL 10 3 (30.0 %)
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67, respectively, with slightly better agreement between VIA/
VILI and p16INK4a/Ki-67 than between VIA/VILI and HPV
DNA testing (kappa −0.003 (HPV) and 0.030 (p16INK4a/Ki-
67), respectively; overall positive and negative agreement
77.1 % (HPV) and 89.5 % (p16INK4a/Ki-67)). Of the 15
VIA/VILI positive women, only 3 were tested positive
for HPV DNA and 2 positive for p16INK4a/Ki-67.
A moderate agreement was observed between HPV
and p16INK4a/Ki-67 results (kappa = 0.437, p < 0.001)
with total positive and negative agreement of 85.5 %.
The majority of samples positive for p16INK4a/Ki-67 were
also positive for HPV DNA (35/39), however more than
half of HPV DNA positive samples were p16INK4a/Ki-67
negative (65/100).
Performance of the tests to detect high grade cervical
intraepithelial neoplasia
The histopathology of a biopsy is considered as the
gold-standard for the diagnosis of cervical dysplasia.
Women were invited to colposcopy and biopsy if at least
one of the tests VIA/VILI, Pap cytology, HPV DNA,
and/or p16INK4a/Ki-67 was positive. Women with only
negative test results were considered as disease negative.
Of the 22 women which appeared for colposcopy, 4 had
no visible lesion and were thus not biopsied, 8 had nor-
mal histology in the punch biopsies, 2 women had
CIN1, 2 had CIN2 and 6 women were diagnosed with
CIN3. All biopsies were evaluated independently from
H&E evaluation for p16INK4a expression and all CIN2
and CIN3 lesions showed positive diffuse p16INK4a ex-
pression, while normal and CIN1 cases were p16INK4a-
negative, thus supporting the diagnosis of high-grade
dysplasia in 8 women (2 CIN2, 6 CIN3).
The 6 lesions diagnosed as CIN3 and the two lesions di-
agnosed as CIN2 in a punch biopsy were all not positiveresults in relation to Pap cytology and colposcopy/biopsy.
included in the normal histology group
HPV DNA positive p16INK4a/Ki-67 positive
11 (91.7 %) 1 (8.3 %)
2 (100.0 %) 0 (0.0 %)
2 (100.0 %) 1 (50.0 %)
6 (100.0 %) 6 (100.0 %)
79 31
76 (17.8 %) 18 (4.2 %)
11 (78.6 %) 7 (50.0 %)
1 (100.0) 1 (100.0)
4 (15.4 %) 6 (23.1 %)
8 (80.0 %) 7 (70.0 %)
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DNA testing detected all of these high grade lesions, but
was also positive in 91.7 % (11/12) of women with normal
histology. p16INK4a/Ki-67 cytology was positive in all 6
CIN3 lesions, in one of the two CIN2 lesions and in only
8.3 % (1/12) of women with normal histology in the punch
biopsy (Table 1).
As an additional estimate of dysplasia detection rates,
the proportion of positive VIA/VILI, HPV DNA and
p16INK4a/Ki-67 results in relation to Pap cytology were
assessed. VIA/VILI was positive in only 30 % (3/10) of
women with HSIL cytology. HPV DNA testing was posi-
tive in 80 % (8/10) of women with HSIL cytology, but also
positive in 17.8 % (76/426) of women with negative Pap
cytology. p16INK4a/Ki-67 dual stain cytology was positive
in 70 % (7/10) women with HSIL cytology and only 4.2 %
(18/426) women with normal cytology (Table 1).
Discussion
The high incidence of cervical cancer in Kenya and
other developing countries is amongst other reasons due
to lacking opportunities for early detection followed by
treatment of pre-invasive lesions when necessary.
Visual inspection (VIA and VILI) is used in some set-
ting with variable sensitivity and specificity [10]. HPV
DNA testing is being evaluated in developing countries
as a more objective test with higher sensitivity and lim-
ited specificity [19]. The aim of the present study was
to evaluate p16INK4a/Ki-67 dual-stain cytology in a
screening population of Kenyan women in comparison
to HPV DNA testing and VIA/VILI. p16INK4a is a
marker with a potentially favorable diagnostic profile,
i.e. low rate of false-positive test results and high de-
tection rate of disease [17, 20].
HPV DNA testing yielded the highest rate of overall
positive results (20.9 %; 100/477) in our study with high-
est HPV prevalence in women younger than 21 years.
Among women with available colposcopy and biopsy
HPV DNA testing detected all women with histologically
confirmed high grade lesions (n = 8), but was also posi-
tive in 91.7 % (11/12) of women with normal histology.
p16INK4a/Ki-67 cytology yielded a lower overall rate of
positive results (8.2 %; 39/477) and most importantly no
positives in women younger than 21 years. This indicates
that the test does not pick up the many transient and
non-transforming HPV infections in this age group that
most likely do not need to be treated. Furthermore
p16INK4a/Ki-67 cytology was positive in all 6 women
with CIN3 lesions, in one of the two CIN2 lesions and
in only 8.3 % (1/12) of women with normal histology in
the punch biopsy.
In our study p16INK4a/Ki-67 cytology staining was per-
formed in an experienced laboratory in Heidelberg,
Germany. However, the availability as ready-to-usereagents and little technical equipment which is required
might give the opportunity to implement it in an envir-
onment with less advanced infrastructure. We used the
PreservCyt ThinPrep system for cytology preparations in
the study as this allowed to use one cervical swab for all
tests. However, p16INK4a/Ki-67 cytology staining can also
be performed on conventional cytology smears. There is
no published data on direct comparison of p16INK4a/Ki-
67 cytology using both cytologic methods (liquid-based
vs conventional) for the same woman; there was how-
ever no significant difference in p16INK4a/Ki-67 cytology
performance between women screened with conven-
tional smears compared to women screened with liquid-
based cytology demonstrated in a large European primary
screening study [17].
In the present study we solely evaluated the diagnostic
performance of the tests; we however would like to point
out that there is an urgent need now to complement diag-
nostic studies by well-designed cost-effectiveness analyses.
Presently p16INK4a/Ki67, particularly in combination with
the ThinPrep system cannot be regarded as affordable for
low-resource settings. On the long run however cost-
effectiveness will largely depend on incentives of minis-
tries, industry and finally the performance of the used
tests. In this regard the present study may add an import-
ant data set for upcoming initiatives and cost analyses.
VIA/VILI, which is currently used in some regions in de-
veloping countries, detected none of the women with histo-
logically proven CIN2+, thus women would have been
missed by the test. VIA/VILI has the advantage that it is
cheap, requires no advanced equipment and can be used as
a point-of-care test allowing for screening and cryotherapy
if necessary on the same day. However its diagnostic per-
formance can be poor, as indicated by our result.
Conclusions
Although the sample size is limited by the low number
of women which followed the invitation to colposcopy
and biopsy, it is a promising finding that p16INK4a/Ki-67
testing yielded a similar detection rate of CIN2+ and a
substantially lower rate of positive tests in women with
negative histology compared to HPV DNA. Moreover,
the overall lower test positivity rate particularly in young
women of p16INK4a/Ki-67 compared to HPV DNA test-
ing suggests that only little transient infections are
picked up and warrants further evaluation of the test in
countries with high HPV prevalence. p16INK4a/Ki-67 cy-
tology can be performed within 5 hours manually and
does not necessarily require technical equipment except
a heating bath and a microscope, thus potentially being
performed at a health facility within one day under stan-
dardized and controlled conditions. Assessing the slides
does not require morphological interpretation, positive
are considered all slides with one or more cells
Table 2 Agreement between VIA/VILI, HPV results and
p16INK4a/Ki-67 cytology. Shown are absolute numbers of
positive and negative samples for the three tests
p16INK4a/Ki-67 VIA/VILI
Negative Positive Negative Positive
HPV DNA Negative 373 4 365 12
Positive 65 35 97 3
VIA/VILI Negative 425 37
Positive 13 2
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be learned in a brief training session even by people
without prior cytologic or pathologic training [21]. For
further studies also automated software-based evalua-
tions of the slides are well conceivable [22].
Methods
Study design
The rate of positive test results and diagnostic perform-
ance of VIA/VILI, HR-HPV DNA detection and
p16INK4a/Ki-67 dual-stain cytology was evaluated in a
cross-sectional study in women living in Thika district,
Kenya. Liquid-based cytology (LBC) samples were taken
and sent to Heidelberg, Germany, where HR-HPV DNA
testing and p16INK4a/Ki-67 immunostaining was per-
formed. Additionally, Pap staining was performed from
the LBC sample in Heidelberg. According to the study
protocol, women with a positive VIA/VILI and/or HR-
HPV and/or p16INK4a/Ki-67 test, and/or Pap cytology
result were invited for colposcopy/biopsy to obtain a
histopathologic diagnosis followed by treatment in cases
were indicated. With the limitation that a sole positive
HR-HPV DNA test only resulted in immediate colpos-
copy in women older than 30 years.
Ethical approval was obtained from the National Eth-
ical Review Committee at the Kenya Medical Research
Institute and women who agreed to participate signed
an informed consent form.
Recruitment of women and cervical sampling
Women were recruited for the study in Thika District,
Kenya in February 2010. The population is both rural and
urban. Women who live in this region were invited to par-
ticipate in the study through posters placed at markets
places, churches, and health centers. Women were eligible
for the study if they were (a) self-identified as residing in
the region, (b) were ages 18 and above, (c) had an intact
uterus, (d) did not report the use of vaginal medication for
the previous two days, (e) did not report treatment for cer-
vical disease for the previous 6 months, and (f) were not
pregnant at the time of the study.
Cervical cells were collected by female nurses using the
liquid-based cytology ThinPrep® Pap test Kit (Hologic,Bedford, USA) according to manufacturer’s instruction and
stored in the PreservCyt solution vial (Hologic, Bedford,
USA) at ambient temperature. All tests, Pap cytology,
p16INK4a/Ki-67 cytology, and HR-HPV DNA detection
were performed from the same vial at the Department of
Applied Tumor Biology, Heidelberg, Germany. VIA/VILI
was performed by the nurses after the cytology sample was
taken and documented in a standard form.
Pap cytology
ThinPrep® slides were stained according to routine Pap
staining laboratory protocols. All Pap cytology slides
were read blinded to all other results at the Institute of
Pathology, A2, Mannheim, Germany by an experienced
cytotechnologist and gyneco-pathologist. The result was
reported according to the Bethesda system.
p16INK4a/Ki-67 dual-stain cytology
A second ThinPrep® slide was prepared from all samples
and stained manually with a mix of two monoclonal anti-
bodies against p16INK4a and Ki-67, respectively using the
CINtec PLUS kit (Roche mtm Laboratories, Heidelberg,
Germany) according to the manufacturer’s instructions.
The cervical cancer cell line C4-1 was used as positive con-
trol. The dual-staining results in brown visualization of
p16INK4a protein and red visualization of Ki-67 protein.
Samples were considered as p16INK4a/Ki-67 dual-stain posi-
tive when at least one cell was visible on the slide under a
light microscope expressing both proteins, thus if at least
one cell was found with a red nucleus (Ki-67) surrounded
by brown cytoplasm (p16INK4a).
High-risk human papillomavirus detection
After processing for cytology, four mls of residual Pre-
servCyt® solution was used for HR-HPV detection. The
HR-HPV detection was carried out using the Hybrid
capture 2® (hc2) test (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. A positive hc2 re-
sult was defined as RLU/Co ≥ 1.
Colposcopy, biopsy and histology
Colposcopy was performed at Thika District Hospital by
an experienced gynecologist. Four to five punch biopsies
were taken from the cervix of women with visible le-
sions. The tissue was placed in formalin and embedded
in paraffin for hematoxylin & eosin staining. The slides
were assessed by an experienced pathologist at Institute
of Pathology, A2, Mannheim, Germany. A second sec-
tion from all biopsies was stained immunohistochemi-
cally for p16INK4a (CINtec histology, mtm Laboratories,
Heidelberg) and slides with a diffuse p16INK4a expression
beginning in the basal and parabasal cell layers were
considered as p16INK4a histology positive.
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Results were computed as number of positive and nega-
tive test results in the entire study cohort, in different
age groups and separated for cyologic and histologic
diagnosis. Inter-assay agreements were assessed using
Cohen's kappa statistics.
Women with negative VIA/VILI, HPV DNA, p16INK4a/
Ki-67 and Pap cytology test were considered as disease
negative. Women with a positive VIA/VILI and/or HR-
HPV and/or p16INK4a/Ki-67 test, and/or Pap cytology re-
sult were invited for colposcopy/biopsy to obtain a histo-
pathologic diagnosis (CIN2, CIN3+). Women who
showed up for colposcopy but had a normal appearing
cervix were not biopsied and were considered as disease
negative. Since most women with positive screening test
results did not show up for colposcopy as per protocol,
a gold standard disease endpoint for the evaluation of
the diagnostic performance of the tests was only avail-
able for a subset of study participants. Prevalence of
positive test results and agreements of the different tests
was assessed in the entire study population.
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